| Need for consensus on primary endpoints and efficacy definitions in trials for adult acute lymphoblastic leukemia MJ Wieduwilt Blood Advances, 2024 | | 2024 |
| Precision Oncology in Hematological Malignancies: Takeaways from the 2023 Precision Oncology Summit AM Khan, I Abuali, H Abrams, I Riano, KT Larkin, M Wieduwilt, ... International Journal of Cancer Care and Delivery, 2024 | | 2024 |
| Long-Term Follow up for SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive Acute Lymphoblastic … AS Advani, AB Moseley, KM O'Dwyer, BL Wood, JH Park, MJ Wieduwilt, ... Blood 142, 1499, 2023 | | 2023 |
| Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage … SM Luger, Z Sun, RJ Mattison, E Paietta, KG Roberts, Y Zhang, ... Blood 142, 2877, 2023 | 3 | 2023 |
| P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7+ 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5 … E Ritchie, TL Lin, LF Newell, RK Stuart, S Solomon, R Stone, G Schiller, ... HemaSphere 7 (S3), e7753968, 2023 | | 2023 |
| S117: Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly-diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic … M Wieduwilt, J Yin, O Kour, R Teske, W Stock, K Byrd, K Doucette, ... HemaSphere 7, e08838b7, 2023 | 4 | 2023 |
| S115: consolidation with blinatumomab improves overall and relapse-free survival in patients with newly diagnosed B-cell acute lymphoblastic leukemia: impact of age and mrd … M Litzow, Z Sun, R Mattison, E Paietta, C Mullighan, K Roberts, Y Zhang, ... HemaSphere 7, e1944062, 2023 | 2 | 2023 |
| UCHMC 1812: A phase 1b trial of CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myeloid leukemia. DL Gaut, B Callas, LE Damon, BA Jonas, D Jeyakumar, C Borror, ... Journal of Clinical Oncology 41 (16_suppl), 7024-7024, 2023 | | 2023 |
| Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia … MJ Wieduwilt, J Yin, O Kour, R Teske, W Stock, K Byrd, K Doucette, ... Journal of Clinical Oncology 41 (16_suppl), 7006-7006, 2023 | 15 | 2023 |
| Survival outcomes with CPX-351 vs 7+ 3 by baseline bone marrow blast percentage in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: A 5-year … EK Ritchie, TL Lin, LF Newell, RK Stuart, SR Solomon, RM Stone, ... Journal of Clinical Oncology 41 (16_suppl), 7027-7027, 2023 | | 2023 |
| Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia AS Advani, A Moseley, KM O’Dwyer, BL Wood, J Park, M Wieduwilt, ... Blood advances 7 (7), 1279-1285, 2023 | 19 | 2023 |
| North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need N Pemmaraju, H Kantarjian, K Sweet, E Wang, J Senapati, NR Wilson, ... Blood 141 (6), 567-578, 2023 | 24 | 2023 |
| Adapting the HCT-CI definitions for children, adolescents, and young adults with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation BD Friend, L Broglie, BR Logan, S Chhabra, C Bupp, G Schiller, ... Transplantation and cellular therapy 29 (2), 123. e1-123. e10, 2023 | 9 | 2023 |
| Extracorporeal photopheresis for the treatment of chronic graft versus host disease E Kansu, D Ward, AP Sanchez, R Cunard, M Hayran, B Huseyin, ... Hematology 27 (1), 785-794, 2022 | 3 | 2022 |
| Ph+ ALL in 2022: is there an optimal approach? MJ Wieduwilt Hematology 2022 (1), 206-212, 2022 | 4 | 2022 |
| Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease … MR Litzow, Z Sun, E Paietta, RJ Mattison, HM Lazarus, JM Rowe, ... Blood 140 (Supplement 2), LBA-1-LBA-1, 2022 | 66 | 2022 |
| Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity H Abdulhaq, O Mahmood, CKJ Chen, A Borogovac, M Wieduwilt, ... Blood 140 (Supplement 1), 3553-3554, 2022 | | 2022 |
| Transplant outcomes after CPX-351 vs 7+ 3 in older adults with newly diagnosed high-risk and/or secondary AML GL Uy, LF Newell, TL Lin, SL Goldberg, MJ Wieduwilt, RJ Ryan, S Faderl, ... Blood Advances 6 (17), 4989-4993, 2022 | 9 | 2022 |
| Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center A Borogovac, A Keruakous, M Bycko, J Holter Chakrabarty, S Ibrahimi, ... Bone marrow transplantation 57 (6), 1025-1027, 2022 | 40 | 2022 |
| Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia VE Kennedy, G Hui, T Azenkot, D Gaut, MJ Wieduwilt, C Oliai, BA Jonas, ... American journal of hematology 97 (6), E191-E194, 2022 | 12 | 2022 |
